Balchem Secures Enhanced Credit Facility With $100 Million Capacity Increase and Four-Year Extension

Expanded Borrowing Capacity Strengthens Liquidity Position

Balchem Corporation's amendment to its credit agreement represents a material enhancement to the company's liquidity profile. The $100 million increase in revolving credit capacity—from $550 million to $650 million—provides the Maryland-based chemical specialty company with substantially greater financial flexibility to manage working capital, fund growth initiatives, and navigate operational demands. The expanded commitment was achieved through the Credit Agreement Amendment signed on July 24, 2026, with JPMorgan Chase Bank, N.A. and JPMorgan SE serving as administrative agents for the lending syndicate.

This expansion of borrowing capacity is notable given the competitive lending environment and reflects lenders' assessment of Balchem's creditworthiness and operational performance. The company operates in the specialty chemicals sector, which requires substantial working capital to maintain inventory and support customer relationships. The additional $100 million in available liquidity provides management with enhanced flexibility to respond to market opportunities, manage seasonal fluctuations in business, and pursue strategic acquisitions or capital investments without requiring immediate refinancing or equity dilution.

Extended Maturity Provides Multi-Year Certainty

The extension of the credit facility's maturity date from July 27, 2027, to July 24, 2031, represents a significant extension of Balchem's financial runway. By pushing the maturity four years into the future, the company eliminates near-term refinancing risk and provides management with greater certainty regarding the long-term availability of credit. This extended timeline is particularly valuable in uncertain economic conditions and allows Balchem to focus on organic growth and operational execution rather than managing refinancing logistics.

The four-year extension also demonstrates the lenders' willingness to commit capital to Balchem on an extended basis, which may be interpreted by investors as a positive signal regarding the sustainability of the company's business model and financial condition. Extended credit facility maturities typically require lenders to maintain confidence in a borrower's ability to service debt and maintain acceptable financial metrics throughout the duration of the facility. The July 24, 2031, maturity date aligns with management's strategic planning horizons and reduces uncertainty regarding refinancing obligations during that period.

Pricing Grid Adjustments and Borrowing Cost Improvements

The amended credit agreement includes material improvements to Balchem's borrowing costs through elimination of a 10 basis point adjustment to the applicable SOFR rate and reductions to applicable margins at higher leverage tiers. Specifically, the amendment reduced the applicable margin for loans at Tier 3 and Tier 4 leverage levels by 12.5 basis points in each tier, with corresponding reductions to base rates. The revised pricing grid establishes four pricing tiers based on the Consolidated Net Leverage Ratio as calculated under the amended agreement.

Under the new pricing structure, Balchem's borrowing costs will vary based on leverage performance: Tier 1 (leverage below 1.00:1.00) features a 1.00 percent applicable rate for benchmark and RFR loans with 0 percent letter of credit fees; Tier 2 (leverage 1.00:1.00 to 2.00:1.00) carries 1.125 percent rates and 0.125 percent letter of credit fees; Tier 3 (leverage 2.00:1.00 to 3.00:1.00) features 1.250 percent rates and 0.250 percent letter of credit fees; and Tier 4 (leverage 3.00:1.00 and above) carries 1.500 percent rates and 0.500 percent letter of credit fees. These rate reductions directly lower Balchem's cost of capital and improve net interest expense, benefiting earnings quality.

Foreign Borrower Capability and International Flexibility

The amended credit agreement now enables Balchem B.V., the company's foreign subsidiary, to borrow funds directly under the facility. This expansion of borrowing capacity to international operations provides Balchem with enhanced flexibility to manage cash flows and working capital across its global footprint. The addition of foreign borrower capability allows the company to optimize its capital structure and reduce the need for intercompany loans or other financing arrangements that may be less efficient from a tax or operational perspective.

The Foreign Borrower designation reflects Balchem's international operational footprint and the global nature of its specialty chemicals business. By enabling direct borrowing by Balchem B.V., the amended agreement allows the company to fund European or other international operations more efficiently and respond quickly to working capital needs in foreign markets without requiring approvals or delays associated with intercompany financing structures. This structural enhancement to the credit facility underscores the syndicate's willingness to support Balchem's international growth and operational management.

Security and Guarantor Structure Reaffirmed

The disclosure indicates that Balchem and certain domestic subsidiaries entered into an Omnibus Reaffirmation and Amendment Agreement that reaffirms the terms of the Amended and Restated Security and Pledge Agreement originally dated July 27, 2022. The reaffirmation agreement acknowledges that the obligations and liens pursuant to the security agreement remain in effect. This structural continuity ensures that the security interests and guarantor obligations supporting the credit facility remain in place under the amended terms.

The involvement of domestic subsidiaries as guarantors provides additional credit support to the lending syndicate and reflects standard market practice for facilities supporting large specialty chemicals companies. The security structure ensures that lenders maintain collateral coverage and priority claims on company assets in the event of default, which typically allows borrowers to achieve more favorable pricing and terms. The reaffirmation of existing security arrangements under the amended facility suggests that no material changes to collateral or guarantor structures were necessary to accommodate the increased commitment and extended maturity.

JPMorgan Chase Syndicate and Administrative Arrangement

The credit facility is administered by JPMorgan Chase Bank, N.A. and JPMorgan SE, serving as joint administrative agents. The involvement of JPMorgan Chase in both administrative and lending roles reflects the bank's significant relationships with Balchem and its confidence in the company's creditworthiness. JPMorgan Chase's continued participation and willingness to expand its commitment under the amended agreement provides additional validation of Balchem's financial stability and business prospects.

The administrative agent structure typically involves one or more lead banks coordinating the lending syndicate, managing documentation, processing payments, and monitoring compliance with financial covenants and other facility terms. JPMorgan Chase's role as administrative agent indicates that the bank maintains detailed knowledge of Balchem's business, financial condition, and covenant compliance. The decision to expand the facility and extend its maturity likely reflects positive assessments of the company's operating performance and financial trajectory from the administrative agents and the broader lending syndicate.

Investor Considerations and Financial Flexibility Impact

The expanded credit facility and extended maturity provide Balchem with significantly enhanced financial flexibility and reduced near-term refinancing risk. Investors may view the successful amendment as a positive signal regarding lender confidence in the company's business fundamentals and debt service capacity. The increased borrowing capacity of $100 million provides management with additional dry powder to pursue strategic opportunities, fund capital investments, or strengthen the balance sheet as business conditions warrant.

The improvement in borrowing costs through basis point reductions and elimination of the SOFR adjustment will benefit Balchem's net interest expense and reported earnings on an ongoing basis. The magnitude of these savings will depend on the company's average borrowing levels and leverage tier classification, but the directional impact on profitability is favorable. Over the four-year extended maturity period, the cumulative benefit of improved pricing could be material to shareholder returns and financial performance metrics.

Limitations and Investor Disclosures

The company noted in the disclosure that the representations, warranties, and covenants contained in the loan documents were made solely for the benefit of the parties to the agreements and are subject to limitations and standards of materiality that may differ from those applicable to public investors. The filing emphasizes that investors should not rely on representations and warranties contained in the loan documents as accurate characterizations of Balchem's actual financial or operational condition.

The company further noted that information concerning the subject matter of representations and warranties may change after the date the loan documents are executed, and such subsequent changes may not be fully reflected in public disclosures. This standard disclaimer protects the company and lenders from being bound by outdated representations but underscores the importance of investors reviewing Balchem's ongoing regulatory filings, quarterly earnings reports, and other public disclosures for current information regarding financial condition and business performance. The full text of the amended credit agreement and related loan documents are available as exhibits to the current report and contain complete terms, conditions, and covenants governing the facility.